Musculoskeletal

Sarcomas: presentation and referral

Clinical Overview and When to Suspect Sarcoma

— Soft tissue sarcoma (STS): liposarcoma, leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma, GIST, angiosarcoma, rhabdomyosarcoma

— Bone sarcoma: osteosarcoma (bimodal — adolescents and elderly with Paget's/prior radiation), Ewing sarcoma (children/young adults), chondrosarcoma (middle-aged adults)

— Soft tissue mass that is >5 cm, deep to fascia, growing, or painful (any one feature warrants imaging + referral)

— Recurrence of a previously "benign-appearing" lump after local excision

— Bone pain that is deep, persistent, night/rest pain, not activity-related — distinguishes from mechanical/overuse

— Pathologic fracture through a lytic lesion in a young patient

— Prior therapeutic radiation (angiosarcoma of breast post-lumpectomy + XRT; UPS in radiation field, 5–10 yr latency)

— Chronic lymphedema → Stewart-Treves angiosarcoma (post-mastectomy arm)

— Li-Fraumeni (TP53), NF1 (MPNST from neurofibroma), hereditary retinoblastoma (osteosarcoma), Paget disease of bone, familial GIST (KIT)

— Vinyl chloride, thorotrast → hepatic angiosarcoma

Sarcomas are rare malignancies of mesenchymal origin arising from soft tissue (fat, muscle, fibrous tissue, nerve sheath, vessel) or bone — together <1% of adult cancers (~13,000 soft tissue + ~3,500 bone cases/year in US), but disproportionately tested because delayed referral is a known patient safety failure.

Two broad families:

When to suspect — the Step 3 trigger phrases:

Risk factors / syndromes to recognize on stems:

Board pearl: The single most tested mistake is the "shelled-out lipoma" — a primary care or general surgery excision of an unbiopsied deep mass that turns out to be sarcoma, contaminating tissue planes and worsening limb-salvage odds. Any deep or >5 cm soft tissue mass needs MRI and referral to a sarcoma center BEFORE biopsy or excision.

Presentation Patterns and Key History

— Painless, enlarging extremity mass (thigh most common site, ~40%) noticed over weeks–months

— Patient often attributes to trauma ("hit my leg playing softball"); trauma does not cause sarcoma but draws attention to a pre-existing mass — do not be reassured by the history of injury

— Retroperitoneal sarcoma (liposarcoma, leiomyosarcoma): vague abdominal fullness, early satiety, back pain, lower extremity edema from IVC compression, palpable abdominal mass on exam — frequently mistaken for "constipation" or hernia

— Osteosarcoma: teenager with knee pain (distal femur, proximal tibia), worse at night, low-grade fevers possible; or elderly patient with Paget disease developing new bone pain

— Ewing: child/adolescent with diaphyseal pain + systemic symptoms (fever, weight loss, elevated ESR/LDH) — mimics osteomyelitis

— Chondrosarcoma: adult >40 with deep pelvic/proximal femoral pain

— Size — is it >5 cm?

— Growth — has it changed?

— Depth — superficial vs deep to fascia?

— Pain — present, especially at night?

— Duration and prior excision attempts

Soft tissue sarcoma — classic stem:

GIST: GI bleeding (occult anemia or melena), early satiety, incidental submucosal mass on EGD/CT; stomach (60%) > small bowel

Bone sarcoma — classic stems:

Red flag history checklist (must elicit on every soft tissue mass):

Key distinction: Lipoma vs liposarcoma — lipomas are typically <5 cm, soft, mobile, superficial (subcutaneous), and stable for years. Any deep-seated fatty mass, >5 cm, or growing mandates MRI; "lipoma" is a clinical diagnosis only when classic features are present, otherwise it is a soft tissue mass of unknown type.

Step 3 management: On a primary care visit with a >5 cm or deep soft tissue mass, the next step is MRI with contrast, not reassurance or excisional biopsy. Document size, depth, and growth trajectory — these drive urgent referral.

Physical Exam Findings

— Size: measure in two dimensions; >5 cm is a sarcoma red flag (the "5 cm rule")

— Depth: is it mobile over fascia (superficial, lower risk) or fixed and deep (concerning)? Subfascial masses are sarcoma until proven otherwise

— Consistency: firm/rubbery vs soft/doughy (lipomas); sarcomas often firm, non-tender

— Mobility: fixation to underlying structures suggests invasion

— Overlying skin: ulceration, induration, telangiectasia (angiosarcoma — often violaceous patches mistaken for bruise on scalp/face in elderly)

— Neurovascular exam distal to mass: sensory/motor deficit, pulses, edema — implicates neurovascular bundle involvement

— Regional lymph nodes: most sarcomas are hematogenous; nodal spread is uncommon except synovial, epithelioid, clear cell, rhabdomyosarcoma, angiosarcoma (mnemonic: SCARE)

— Localized tenderness, palpable mass over long bone, decreased ROM of adjacent joint

— Warmth and erythema can mimic infection (especially Ewing)

— Examine for pathologic fracture signs; check for café-au-lait, neurofibromas (NF1 → MPNST), retinoblastoma scars

— Palpable abdominal mass, often non-tender, crossing midline

— Lower extremity edema (IVC/iliac compression), varicocele (left renal vein), flank fullness

Soft tissue mass exam — systematic approach:

Bone sarcoma exam:

Retroperitoneal/abdominal sarcoma:

Pulmonary exam: sarcomas metastasize hematogenously to lung first — examine for decreased breath sounds, effusion

Constitutional: weight loss, fatigue suggest advanced disease; Ewing classically with fever

Board pearl: A violaceous, bruise-like patch on the scalp of an elderly patient that does not resolve is cutaneous angiosarcoma until proven otherwise — biopsy promptly; mortality is high and lesions are often dismissed as ecchymosis or rosacea.

Key distinction: Lymphadenopathy does not rule sarcoma in or out for most subtypes — drives biopsy decisions toward carcinoma/lymphoma workup instead, a common stem trap.

Diagnostic Workup — Initial Imaging and Labs

— MRI with and without contrast of the primary site is the imaging study of choice for extremity, trunk, and head/neck soft tissue masses; defines size, depth, fascial relationships, neurovascular involvement, and surgical planning

— Ultrasound acceptable for superficial small (<5 cm) masses that look clinically benign (simple lipoma, ganglion, sebaceous cyst); if any atypical features → MRI

— CT preferred for retroperitoneal/abdominal sarcomas (better for fat planes, lung mets staging)

— Plain radiographs first — assess pattern: lytic vs blastic, periosteal reaction (Codman triangle, sunburst → osteosarcoma; onion-skin → Ewing), matrix mineralization

— Follow with MRI of entire involved bone to assess marrow extent, skip lesions, soft tissue component

— CT chest for all sarcomas — lung is dominant metastatic site (~80% of sarcoma mets)

— Bone scan or PET-CT for bone sarcomas; PET increasingly used for high-grade STS

— Abdominal/pelvic CT for myxoid/round cell liposarcoma (atypical extrapulmonary mets), retroperitoneal sarcoma, leiomyosarcoma

— CBC, CMP, LDH (elevated in Ewing — prognostic), ALP (osteosarcoma — prognostic), ESR

— No serum tumor marker is diagnostic for sarcoma; labs are baseline for chemo eligibility

1. History + exam → identify red flags (>5 cm, deep, growing, painful)

2. MRI with contrast

3. If MRI suspicious → refer to sarcoma center BEFORE biopsy

4. Image-guided core needle biopsy along a planned surgical tract

5. CT chest for staging

Soft tissue mass — initial imaging:

Bone lesion — initial imaging:

Staging imaging once sarcoma suspected:

Labs:

Step 3 management sequence for an unknown soft tissue mass:

Board pearl: Ordering an excisional biopsy first ("just take it out and send to path") is the highest-yield wrong answer. It contaminates tissue planes, mandates wider re-excision or amputation, and worsens outcomes. Always image → refer → core biopsy at sarcoma center.

Diagnostic Workup — Biopsy and Confirmatory Studies

— Image-guided core needle biopsy is preferred — preserves tissue planes, allows histology + grade + molecular studies

— Biopsy tract must be placed by the surgeon who will do definitive resection — the tract is excised en bloc with the tumor; a poorly placed tract turns a limb-salvage case into an amputation

— Incisional biopsy acceptable if core nondiagnostic; longitudinal incision on extremity, never transverse

— Excisional biopsy only for small (<3 cm), superficial, clinically benign-appearing lesions

— FNA is inadequate for primary sarcoma diagnosis (insufficient architecture) but useful for confirming recurrence/mets

— Ewing sarcoma → t(11;22) EWSR1-FLI1

— Synovial sarcoma → t(X;18) SS18-SSX

— Myxoid liposarcoma → t(12;16) FUS-DDIT3

— Alveolar rhabdomyosarcoma → PAX3/PAX7-FOXO1

— GIST → KIT (CD117) or PDGFRA mutations; DOG1+

— Dermatofibrosarcoma protuberans → COL1A1-PDGFB

— Clear cell sarcoma → EWSR1-ATF1

Biopsy principles (heavily tested):

Histopathology and molecular signatures (high-yield associations):

Grading: FNCLCC grade (1–3) based on differentiation, mitotic count, necrosis — single most important prognostic factor in STS along with size and depth

Staging: AJCC 8th edition uses TNM + grade; size cutoffs 5, 10, 15 cm

Key distinction: Grade > stage > histologic subtype for predicting metastatic risk in STS. A 6 cm grade 1 liposarcoma behaves very differently from a 6 cm grade 3 UPS.

Step 3 management: When a stem says "PCP performed excisional biopsy of a 7 cm thigh mass and pathology shows high-grade sarcoma with positive margins" — the next step is MRI of the surgical bed + CT chest + referral to sarcoma center for re-excision (wider margins) ± radiation, not observation. Unplanned excision ("whoops procedure") mandates re-excision in nearly all cases.

Risk Stratification and Management Logic

— Tumor grade (FNCLCC 1–3) — strongest predictor

— Size (>5 cm, >10 cm thresholds)

— Depth (deep > superficial)

— Histologic subtype (epithelioid, alveolar RMS, angiosarcoma worse)

— Margin status at resection (R0 vs R1/R2)

— Anatomic site (retroperitoneal worse than extremity due to resectability)

— Localized, low-grade, small (<5 cm), superficial: wide local excision alone, R0 margins

— Localized, high-grade or large (>5 cm) or deep: wide excision + radiation (pre- or post-op); ± neoadjuvant chemotherapy for chemo-sensitive subtypes (synovial, myxoid/round cell liposarcoma, UPS)

— Locally advanced/borderline resectable: neoadjuvant chemo ± RT → resection

— Metastatic: systemic chemotherapy (doxorubicin-based), targeted therapy for specific subtypes, palliative resection/RT

— Osteosarcoma & Ewing: neoadjuvant chemo → limb-salvage surgery → adjuvant chemo (cures ~70% of localized disease)

— Chondrosarcoma: surgery alone — chemoresistant and radioresistant

Sarcoma management is multidisciplinary and centralized — outcomes are measurably better at high-volume sarcoma centers (NCCN-designated or equivalent). This is itself a Step 3 health systems testing point.

Prognostic factors for STS:

Treatment framework by stage:

Bone sarcoma framework:

GIST: complete surgical resection (avoid lymphadenectomy — rarely nodal); adjuvant imatinib × 3 yr for high-risk (>5 cm, >5 mitoses/50 HPF, rupture, non-gastric site)

Board pearl: Limb-salvage surgery is achievable in >90% of extremity sarcomas with modern multidisciplinary care; amputation is reserved for unresectable neurovascular involvement or failed limb salvage. The Step 3 wrong answer is "primary amputation."

Step 3 management: For a newly diagnosed extremity sarcoma, the orders to place in CCS-style thinking: MRI primary site, CT chest, core biopsy at sarcoma center, multidisciplinary tumor board referral, baseline labs, and counsel patient on multimodal therapy timeline (3–6 months).

Pharmacotherapy — Systemic Therapy Overview

— Doxorubicin monotherapy (60–75 mg/m² q3wk) — standard first-line for most metastatic STS

— AIM (doxorubicin + ifosfamide + mesna) — higher response rate, used when tumor shrinkage matters (neoadjuvant, symptomatic mets), more toxic

— Gemcitabine + docetaxel — second-line, especially leiomyosarcoma and UPS

— GIST: imatinib 400 mg/day first-line; KIT exon 9 mutations need 800 mg; PDGFRA D842V is imatinib-resistant → avapritinib; resistance → sunitinib → regorafenib → ripretinib

— Dermatofibrosarcoma protuberans: imatinib for unresectable/metastatic

— Rhabdomyosarcoma: VAC (vincristine, actinomycin D, cyclophosphamide)

— Ewing: VDC/IE alternating (vincristine, doxorubicin, cyclophosphamide / ifosfamide, etoposide)

— Osteosarcoma: MAP (high-dose methotrexate, doxorubicin, cisplatin)

— Alveolar soft part sarcoma, epithelioid: pembrolizumab, atezolizumab, pazopanib

— Synovial sarcoma: doxorubicin/ifosfamide; afami-cel (T-cell therapy) emerging

— Doxorubicin: cumulative cardiotoxicity at >450–550 mg/m²; baseline echo/MUGA, repeat per cumulative dose

— Ifosfamide: hemorrhagic cystitis (give mesna), encephalopathy (treat with methylene blue), Fanconi syndrome

— Cisplatin: nephrotoxicity, ototoxicity, neuropathy

— Methotrexate (high-dose): leucovorin rescue, urine alkalinization, monitor levels

Doxorubicin-based regimens are the backbone of STS systemic therapy:

Subtype-specific systemic therapy (highly tested):

Pazopanib (TKI) — FDA-approved for non-adipocytic STS after chemo failure; monitor LFTs, BP, QT

Trabectedin, eribulin — leiomyosarcoma/liposarcoma after anthracycline

Toxicity monitoring essentials:

Step 3 management: Before starting doxorubicin, order baseline LVEF (echo or MUGA). If LVEF <50% or symptomatic CHF, choose liposomal doxorubicin or non-anthracycline regimen. Hold for LVEF drop ≥10% to below 50%.

Board pearl: GIST does NOT respond to conventional cytotoxic chemo — imatinib transformed it from a near-universal killer to a manageable chronic disease. Ordering doxorubicin for metastatic GIST is a stem trap.

Surgical and Radiation Management

— Wide local excision with negative margins (R0) is the cornerstone — typically 1–2 cm of normal tissue or an intact fascial barrier

— En bloc resection including prior biopsy tract

— Limb-salvage achievable in >90% of extremity sarcomas; reconstructive options: endoprosthesis, allograft, rotationplasty (pediatric)

— Retroperitoneal sarcoma: compartmental resection often includes adjacent organs (kidney, colon, psoas) for R0

— GIST: wedge/segmental resection, no lymphadenectomy, avoid tumor rupture (upstages to high-risk)

— Pulmonary metastasectomy: considered for isolated, resectable lung mets with controlled primary — improves survival in selected patients

— Indicated for most high-grade, large (>5 cm), or deep STS to improve local control

— Preoperative RT (50 Gy): smaller field, lower dose, but higher wound complication rate (~35%)

— Postoperative RT (60–66 Gy): larger field, higher dose, more late fibrosis/edema/fracture

— Brachytherapy intraoperatively for select cases

— Bone sarcomas: Ewing is radiosensitive (RT for unresectable or as adjuvant); osteosarcoma and chondrosarcoma are radioresistant — surgery is curative modality

Surgical principles:

Radiation therapy:

Isolated limb perfusion (TNF-α + melphalan): limb-threatening locally advanced extremity sarcoma to convert to resectable

Margin definitions: R0 = microscopically negative; R1 = microscopic positive; R2 = gross residual — R1/R2 mandate re-resection or adjuvant RT

CCS pearl: When managing post-op sarcoma, orders to advance the clock: wound check at 2 weeks, pathology review at multidisciplinary tumor board, initiate adjuvant RT 4–6 weeks post-op if planned, CT chest at 3 months, then surveillance schedule. Document margin status — drives every subsequent decision.

Board pearl: Unplanned excision (sarcoma removed without preoperative diagnosis) is associated with positive margins in 30–60% and mandates MRI of operative bed, restaging, and re-excision — never observation alone.

Special Populations — Elderly and Organ Impairment

— Angiosarcoma of scalp/face disproportionately in elderly — aggressive, often presents late, frequently mistaken for bruise or rosacea

— UPS (undifferentiated pleomorphic sarcoma) is the most common STS in older adults; arises in deep extremity soft tissue

— Secondary osteosarcoma in Paget disease or post-radiation — worse prognosis than primary

— Performance status (ECOG, geriatric assessment) drives treatment intensity; chronologic age alone is not a contraindication

— Doxorubicin tolerability decreased; consider dose reduction, liposomal formulation, or single-agent rather than AIM combination

— Baseline echo essential; many have subclinical LV dysfunction

— Ifosfamide: dose reduce or avoid if CrCl <30; monitor for Fanconi syndrome

— Cisplatin: nephrotoxic — avoid if CrCl <60; substitute carboplatin where possible (e.g., osteosarcoma in CKD)

— High-dose methotrexate: requires CrCl >60, urine alkalinization to pH >7, leucovorin rescue, glucarpidase for delayed clearance

— Pazopanib, sunitinib: mild renal impairment usually tolerated; monitor BP

— Doxorubicin: reduce dose if bilirubin elevated (e.g., 50% reduction for bili 1.2–3.0, 75% for bili >3.0)

— Pazopanib, regorafenib: hepatotoxic — monitor LFTs every 2 weeks initially; hold for ALT >3× ULN

— Imatinib: generally well tolerated; monitor LFTs

— Pre-existing CHF, prior anthracycline exposure → avoid additional doxorubicin or use dexrazoxane cardioprotection

— Hypertension control mandatory before TKIs (pazopanib, sunitinib commonly cause HTN)

Elderly patients (≥70):

Renal impairment:

Hepatic impairment:

Cardiac comorbidity:

Step 3 management: In a 75-year-old with localized 8 cm thigh UPS and EF 45%, the preferred plan is wide local excision + radiation, omit anthracycline-based neoadjuvant chemo due to cardiac risk; consult cardio-oncology, optimize HF therapy, and prioritize local control with acceptable functional outcome.

Board pearl: Dexrazoxane is the only proven cardioprotectant during anthracycline therapy — consider when cumulative doxorubicin approaches 300 mg/m² or in baseline cardiac dysfunction.

Special Populations — Pediatrics and Pregnancy

— Rhabdomyosarcoma — most common pediatric STS; embryonal subtype (head/neck, GU — botryoid bladder, vagina) <10 yr; alveolar subtype (extremities, trunk) adolescents, PAX-FOXO1 fusion, worse prognosis

— Osteosarcoma — peak 10–20 yr, distal femur/proximal tibia/proximal humerus, associated with growth spurts and hereditary retinoblastoma (RB1), Li-Fraumeni (TP53), Paget (older)

— Ewing sarcoma — 10–20 yr, diaphysis of long bones, pelvis, ribs; t(11;22)

— Infantile fibrosarcoma — <1 yr, often ETV6-NTRK3 → larotrectinib responsive

— Always pursue molecular/cytogenetic profiling — drives risk stratification

— Consider fertility preservation (sperm banking, oocyte/ovarian cryopreservation) before alkylators/anthracyclines

— Growth plate considerations in limb-salvage — expandable endoprostheses

— Long-term surveillance for secondary malignancies (AML/MDS from alkylators + etoposide; sarcoma in radiation field)

— Rare but MRI without gadolinium is safe in any trimester; gadolinium avoided especially in 1st trimester

— Surgery safe in 2nd trimester preferentially

— Chemotherapy: avoid 1st trimester (teratogenesis); doxorubicin, ifosfamide, cyclophosphamide tolerated in 2nd/3rd trimester with monitoring

— Radiation to extremity feasible with abdominal shielding distant from fetus; pelvic/abdominal RT contraindicated

— Multidisciplinary consult: maternal-fetal medicine, oncology, surgery; do not delay curative-intent therapy for the pregnancy without informed shared decision-making

Pediatric sarcomas (high-yield epidemiology):

Pediatric workup differences:

Pregnancy and sarcoma:

Key distinction: Embryonal RMS = young child, favorable, often head/neck or GU; Alveolar RMS = adolescent, extremities, PAX-FOXO1, poor prognosis — this is a near-guaranteed Step 3 association.

Step 3 management: A 4-year-old with a vaginal grape-like mass — diagnose botryoid embryonal rhabdomyosarcoma, refer to pediatric oncology, plan VAC chemotherapy + organ-sparing surgery/RT. Avoid radical resection upfront.

Complications and Adverse Outcomes

— Local recurrence — most common adverse outcome of inadequate margins; rate 5–10% with R0 + RT, up to 30–40% with R1 alone

— Pulmonary metastases — dominant pattern (sarcoma = "lung first" malignancy); presents with cough, dyspnea, hemoptysis, or asymptomatic surveillance finding

— Pathologic fracture through bone sarcoma or sarcomatous metastasis

— Tumor lysis syndrome — uncommon but possible with bulky chemosensitive disease (Ewing); prophylactic allopurinol + hydration

— DVT/PE — sarcoma patients (especially retroperitoneal with IVC compression) have high VTE risk

— Anthracycline cardiomyopathy — dose-dependent; symptomatic CHF, decreased LVEF; may be late (years post-treatment)

— Ifosfamide: hemorrhagic cystitis (mesna prevents), encephalopathy (methylene blue), Fanconi syndrome, SIADH

— Cisplatin: sensorineural hearing loss (especially pediatric — audiometry baseline + serial), neuropathy, nephrotoxicity, hypomagnesemia

— High-dose methotrexate: AKI from precipitation, mucositis, hepatotoxicity

— Radiation late effects: lymphedema, joint contracture, fibrosis, pathologic fracture, secondary malignancy (sarcoma in radiation field, 5–10 yr latency)

— Surgical: wound dehiscence (especially pre-op RT field), nerve injury, lymphedema, functional deficit

— Therapy-related MDS/AML — alkylators (cyclophosphamide, ifosfamide) and topoisomerase II inhibitors (etoposide, doxorubicin); latency 3–10 yr; monitor CBC long-term

— Radiation-induced sarcoma in field of prior RT

Disease-related complications:

Treatment-related complications:

Secondary malignancies:

CCS pearl: A sarcoma survivor presenting years later with new dyspnea + decreased exercise tolerance → order echocardiogram first for anthracycline cardiomyopathy before assuming pulmonary metastasis. Both are on the differential but cardiac assessment is non-invasive, fast, and frequently the answer.

Board pearl: Stewart-Treves syndrome = cutaneous angiosarcoma in chronically lymphedematous limb, classically post-mastectomy with axillary node dissection; presents as purple nodules/plaques on edematous arm years after breast cancer treatment.

When to Escalate Care and Referral Pathways

— Soft tissue mass >5 cm, deep to fascia, growing, painful, or recurrent

— MRI showing heterogeneous enhancement, necrosis, neurovascular involvement

— Bone lesion with aggressive radiographic features (cortical destruction, periosteal reaction, soft tissue mass)

— Pathology returning sarcoma after unplanned excision ("whoops procedure")

— Pediatric soft tissue or bone mass — refer to pediatric oncology

— Orthopedic or surgical oncology with sarcoma expertise

— Medical oncology (sarcoma-focused)

— Radiation oncology

— Musculoskeletal radiology

— Sarcoma pathology

— Plastic/reconstructive surgery, PT/OT, social work, genetics

— Pathologic fracture or impending fracture (Mirels score guidance)

— Spinal cord compression from sarcoma or metastasis → emergent MRI, dexamethasone, neurosurgery/radiation oncology

— Hemorrhage from large vascular sarcoma (angiosarcoma, retroperitoneal leiomyosarcoma) → IR, surgery

— Tumor lysis syndrome

— Bowel obstruction from intra-abdominal sarcoma

— Severe neutropenic fever during chemotherapy → admit, broad-spectrum antibiotics within 1 hr, ID/onc

— Sarcoma <45 yr, multiple primary cancers, family history of sarcoma/breast/adrenal/brain → evaluate for Li-Fraumeni (TP53)

— Bilateral retinoblastoma + osteosarcoma → RB1

— Multiple neurofibromas + MPNST → NF1

The single highest-yield Step 3 escalation principle: refer ANY suspected sarcoma to a multidisciplinary sarcoma center BEFORE biopsy or definitive surgery. Outcomes (margin status, limb salvage, survival) are demonstrably better at high-volume centers.

Indications for immediate sarcoma center referral:

Multidisciplinary team composition (Step 3 health systems content):

Inpatient escalation triggers:

Genetic counseling referral:

Step 3 management: "PCP excised a 6 cm thigh mass; path returns high-grade pleomorphic sarcoma, margins positive." Next step = refer to sarcoma center, obtain MRI of operative bed and CT chest — do not initiate chemo or repeat surgery locally. Patient safety hinges on getting them to a sarcoma multidisciplinary team.

Key Differentials — Other Soft Tissue and Bone Masses

— Lipoma: superficial, soft, mobile, <5 cm, stable for years; MRI shows uniform fat signal, no septations >2 mm, no nodularity

— Atypical lipomatous tumor / well-differentiated liposarcoma: deep, larger, septated, nodular on MRI — distinguished from lipoma by MDM2/CDK4 amplification (FISH)

— Hematoma: trauma history, evolving MRI signal, resolves over weeks — but a hematoma that does not resolve or has a solid component is sarcoma until proven otherwise (classic Step 3 trap)

— Abscess: fever, erythema, fluctuance, leukocytosis; aspirate yields pus; rim enhancement with central fluid on MRI

— Myositis ossificans: post-traumatic, peripheral calcification on imaging (opposite of osteosarcoma's central matrix), self-limited

— Desmoid tumor (aggressive fibromatosis): locally infiltrative, non-metastasizing; CTNNB1 (beta-catenin) or APC mutations (Gardner syndrome); treated with observation, sorafenib, or surgery

— Schwannoma/neurofibroma: along nerve, Tinel's sign; NF1 association — concerning for MPNST if rapid growth/pain in neurofibroma

— Ganglion cyst: periarticular, transilluminates, ultrasound-anechoic

— Hemangioma, glomus tumor, nodular fasciitis — benign mimics

— Osteomyelitis: fever, elevated CRP/ESR, MRI marrow edema, can closely mimic Ewing — biopsy may be required

— Osteoid osteoma: night pain relieved by NSAIDs, <2 cm nidus, sclerotic rim

— Giant cell tumor: epiphyseal, lytic, "soap bubble," young adults — locally aggressive, rarely metastasizes

— Enchondroma, fibrous dysplasia, simple bone cyst, aneurysmal bone cyst — benign

— Metastasis or myeloma (older patients) — must always be on differential for lytic lesion >40 yr

Soft tissue mass differentials (same category — mesenchymal/soft tissue):

Bone lesion differentials:

Key distinction: Myositis ossificans has peripheral (zonal) calcification sparing the center; extraskeletal osteosarcoma has central mineralization. Reversing this on imaging is a classic pitfall.

Board pearl: In any adult >40 with a lytic bone lesion, the differential is metastasis > myeloma > primary bone sarcoma — order SPEP/UPEP, CT chest/abd/pelvis, and consider mammography/PSA before assuming primary sarcoma.

Key Differentials — Other-Category Causes

— Metastatic carcinoma to soft tissue or bone — far more common than primary sarcoma in adults >40; common primaries: lung, breast, kidney, thyroid, prostate

— Sarcomatoid carcinoma of lung, kidney, breast — appears spindled, mimics sarcoma; IHC shows keratin positivity

— Carcinosarcoma of uterus (MMMT) — biphasic, treated more like high-grade carcinoma

— Lymphoma — can present as soft tissue or bone mass; biopsy distinguishes; treat very differently

— Multiple myeloma / plasmacytoma — lytic bone lesion, M-protein, hypercalcemia, anemia, renal failure (CRAB)

— Leukemia (chloroma/myeloid sarcoma) — extramedullary myeloid mass

— Langerhans cell histiocytosis — lytic skull lesion in child, "punched-out"

— Osteomyelitis (especially chronic, Brodie abscess) mimics Ewing — fever, ESR, blood cultures, biopsy

— Tuberculous spondylitis (Pott disease) mimics spinal sarcoma — endemic exposure, AFB stain

— Soft tissue abscess — fluctuant, erythematous, leukocytosis

— Hydatid cyst (echinococcus) — endemic exposure, well-defined cystic mass

— AV malformation, pseudoaneurysm — pulsatile mass, bruit, Doppler distinguishes

— Sarcoidosis, IgG4 disease — can produce soft tissue masses

— Brown tumor of hyperparathyroidism — lytic bone lesion + elevated PTH + hypercalcemia

— Gout tophi, calcinosis — soft tissue masses with characteristic imaging

Carcinoma masquerading as sarcoma:

Hematologic malignancies:

Infectious mimics:

Benign vascular/inflammatory:

Endocrine/metabolic:

Key distinction: A 65-year-old smoker with a destructive sacral lesion is far more likely to have renal cell or lung metastasis than primary chondrosarcoma — workup must include cross-sectional imaging of chest/abdomen/pelvis and biopsy before sarcoma-directed therapy.

Board pearl: Anyone >40 with a new bone lesion gets SPEP + UPEP + free light chains to exclude myeloma, plus age-appropriate cancer screening (CT chest, mammography, colonoscopy, PSA) before invoking primary bone sarcoma — this stewardship of workup is a recurring Step 3 theme.

Secondary Prevention and Long-Term Plan

— High-grade STS: H&P + imaging of primary site (MRI or US) + CT chest every 3–6 months × 2–3 years, then every 6 months through year 5, then annually to year 10

— Low-grade STS: H&P + chest imaging (CXR or CT) every 6–12 months × 5 years, then annually

— GIST: post-resection CT abdomen/pelvis every 3–6 months × 5 years based on risk

— Bone sarcoma: local imaging + chest CT every 3 months × 2 yr, then 6 months × 3 yr, then annually

— Cardiac surveillance post-anthracycline: baseline echo, then echo at 1 year and every 3–5 years long-term; symptomatic evaluation lower threshold

— Audiology post-cisplatin (especially pediatric)

— Fertility counseling — chemo-induced ovarian failure, azoospermia

— Endocrine — growth hormone deficiency, hypothyroidism after head/neck or spinal RT

— Secondary malignancy screening — annual CBC for therapy-related MDS/AML; awareness of radiation-induced sarcoma in old RT fields

— Lymphedema management — compression, PT, weight management

— Functional rehabilitation — PT/OT, prosthetics, vocational counseling

— Li-Fraumeni: annual whole-body MRI, breast MRI starting age 20, colonoscopy every 2–5 yr starting 25, dermatologic, neurologic

— NF1: annual skin/neuro exam, monitor neurofibromas for MPNST conversion (new pain, rapid growth)

— Hereditary retinoblastoma: lifelong second-cancer surveillance

There is no proven primary prevention strategy for sporadic sarcoma, but secondary prevention (surveillance for recurrence and second malignancies) is heavily Step 3-relevant.

Surveillance after curative-intent treatment for localized STS (NCCN-aligned):

Long-term survivorship issues:

Genetic syndrome surveillance (when applicable):

Vaccinations and infection prevention during/post-chemo: influenza annually, pneumococcal, COVID; live vaccines deferred during active treatment

Step 3 management: A patient 2 years post-resection of grade 3 thigh leiomyosarcoma asks about follow-up. The correct plan = CT chest + MRI thigh every 3–6 months through year 3, then every 6 months through year 5, then annually, with cardiac echo if treated with anthracycline.

Board pearl: The lungs are the surveillance organ — CT chest is the highest-yield imaging in sarcoma follow-up because pulmonary metastasectomy can be curative for isolated, late-appearing lung mets.

Follow-Up, Monitoring, and Rehabilitation

— Doxorubicin: LVEF (echo) at baseline, every 200 mg/m² cumulative, and at symptoms; consider stopping at 450 mg/m² or earlier with risk factors

— Ifosfamide: urine output, urinalysis (hematuria), mental status, electrolytes (K, Mg, PO4, bicarbonate — Fanconi)

— Cisplatin: CrCl, Mg, audiometry (pediatric), neuropathy assessment

— High-dose MTX: serum levels at 24/48/72 h, urine pH >7, leucovorin until level <0.1 µM

— Pazopanib/sunitinib: BP weekly initially, LFTs every 2 weeks × 2 months, thyroid function (sunitinib), QT

— Imatinib: CBC, LFTs every 1–3 months; edema, muscle cramps common

— Restaging after every 2–3 cycles of chemotherapy

— Pre-operative imaging within 4 weeks of planned surgery

— Post-RT MRI at 3 months baseline (acute changes mimic recurrence — expect this)

— PT/OT initiated pre-op ("prehabilitation") for limb-salvage candidates

— Post-op weight-bearing protocol per reconstruction (endoprosthesis, allograft)

— Lymphedema therapy (manual drainage, compression garments) for inguinal/axillary dissections or RT

— Prosthetic fitting for amputees — typically 4–8 weeks post-op once incision healed

— Psychological support — sarcoma is rare, isolating; refer to social work, support groups

— Signs of local recurrence (new mass, pain, swelling in operative site)

— Signs of pulmonary metastasis (cough, dyspnea, hemoptysis, chest pain)

— Late effects timeline and surveillance plan in writing

— Resumption of activity, return to work, driving (anesthesia, opioid recovery)

— Sun protection of radiation field (lifelong)

Monitoring parameters on active therapy:

Imaging cadence during therapy:

Rehabilitation and functional recovery:

Counseling topics on discharge from acute care:

CCS pearl: On a follow-up visit 6 weeks post-extremity sarcoma resection: orders to advance = wound exam, document neurovascular status, start adjuvant RT planning if not already done, refer to PT, schedule CT chest at 3 months, address pain control taper, and screen for depression/adjustment disorder.

Board pearl: Post-RT MRI changes (edema, enhancement) at 3 months can mimic recurrence — comparison to baseline and serial imaging prevents unnecessary biopsy. Don't biopsy the first abnormal-appearing post-RT MRI without context.

Ethical, Legal, and Patient Safety Considerations

— Disclosure: the patient must be informed transparently (open disclosure / "communication and resolution programs"); failure to disclose violates ethical and often legal duties

— Mitigation: prompt referral to sarcoma center, MRI of operative bed, CT chest, and planned re-excision with wider margins ± RT

— Prevention: any soft tissue mass >5 cm, deep, growing, or painful → image first, refer first, biopsy second

— Limb-salvage vs amputation decision in an adolescent: parental consent + adolescent assent; involve patient in goals of care, body image, athletic aspirations

— Fertility preservation before gonadotoxic chemo: must be discussed and documented before treatment starts — ASCO standard of care; failure to offer is a recurring liability issue

— Clinical trial enrollment: rare-disease setting — patients should be offered trial participation routinely

— Transfer from community surgeon to sarcoma center → ensure pathology slides, imaging discs, and operative report accompany the patient; verify receipt

— Hand-off from pediatric to adult oncology (long-term survivors) — late-effects clinic referral

— Discharge after inpatient chemo → confirm follow-up appointment, neutropenia precautions, emergency contact for fever

— Identifying Li-Fraumeni, NF1, or hereditary retinoblastoma changes surveillance for the entire family; refer to genetics, obtain informed consent for germline testing, address insurance/discrimination concerns (GINA protects health insurance and employment but not life/disability insurance)

— Cancer diagnoses reported to state cancer registry (not patient-optional in most states)

— Adverse events on clinical trials → IRB and sponsor

— Avoid unnecessary excisional biopsies, repeat imaging, or duplicated workup when patient is being referred — centralize at sarcoma center

Patient safety: the unplanned excision ("whoops procedure") — a surgeon excises a presumed lipoma or hematoma without preoperative imaging or biopsy, and pathology returns sarcoma. This is the archetypal sarcoma patient safety failure and is documented in nearly every sarcoma quality improvement literature.

Informed consent edge cases:

Transition of care risks (Step 3 high-yield):

Genetic counseling and family implications:

Mandatory reporting and registry:

Resource stewardship:

Board pearl: When a stem features a "lipoma" excised without imaging that returns as sarcoma, the single best next step is referral to a sarcoma multidisciplinary center, not local re-excision or initiation of chemotherapy. The ethical duty is disclosure and prompt appropriate referral.

High-Yield Associations and Rapid-Fire Facts

— Ewing → t(11;22) EWSR1-FLI1

— Synovial → t(X;18) SS18-SSX

— Myxoid liposarcoma → t(12;16) FUS-DDIT3

— Alveolar RMS → PAX3/7-FOXO1

— DFSP → COL1A1-PDGFB

— Clear cell sarcoma → EWSR1-ATF1

— Infantile fibrosarcoma → ETV6-NTRK3

— Well-differentiated/dedifferentiated liposarcoma → MDM2 amplification

— Li-Fraumeni (TP53) → osteosarcoma, soft tissue sarcoma, breast, adrenal, brain

— NF1 → MPNST (lifetime risk ~10%)

— Hereditary retinoblastoma (RB1) → osteosarcoma

— Gardner/FAP (APC) → desmoid tumors

— Paget disease → secondary osteosarcoma in elderly

— Carney triad → gastric GIST + pulmonary chondroma + paraganglioma

— Thigh — most common STS location (~40%)

— Distal femur/proximal tibia — osteosarcoma

— Diaphysis of long bone — Ewing

— Retroperitoneum — liposarcoma, leiomyosarcoma

— Uterus — leiomyosarcoma

— Stomach — GIST

— Scalp — angiosarcoma (elderly)

— Lymphedematous arm — Stewart-Treves angiosarcoma

— Codman triangle, sunburst → osteosarcoma

— Onion-skin periosteal reaction → Ewing

— Soap bubble lytic lesion in epiphysis → giant cell tumor (benign mimic)

— Popcorn calcification → chondroid matrix (enchondroma/chondrosarcoma)

— Peripheral calcification → myositis ossificans (benign)

— GIST → imatinib

— DFSP → imatinib

— Osteosarcoma → MAP (methotrexate, doxorubicin, cisplatin)

— Ewing → VDC/IE

— Rhabdomyosarcoma → VAC

— STS (general) → doxorubicin ± ifosfamide

Translocations (memorize):

Syndrome–sarcoma pairings:

Site preferences:

Imaging buzzwords:

Drug pairings:

Metastatic pattern: Lung first (hematogenous) for nearly all sarcomas; nodal spread rare except SCARE (Synovial, Clear cell, Angiosarcoma, Rhabdomyosarcoma, Epithelioid).

Board pearl: The "5 cm rule" — any soft tissue mass >5 cm, OR deep to fascia, OR growing, OR painful → MRI + sarcoma referral. If you remember nothing else, remember this.

Board Question Stem Patterns

"A 52-year-old man had a 'lipoma' removed from his thigh by a community surgeon. Pathology returns high-grade pleomorphic sarcoma with positive margins."

— Best next step: MRI of operative bed + CT chest + referral to sarcoma multidisciplinary center for re-excision ± RT. Wrong answers: observation, adjuvant chemo alone, amputation.

"A 15-year-old with 6 weeks of progressive distal thigh pain worse at night. Radiograph shows lytic/sclerotic lesion with sunburst periosteal reaction."

— Diagnosis: osteosarcoma. Next steps: MRI of entire femur, CT chest, alkaline phosphatase, LDH, biopsy at the sarcoma center that will perform definitive surgery.

"A 60-year-old woman with vague abdominal fullness and left leg swelling. CT shows 15 cm heterogeneous fatty retroperitoneal mass."

— Diagnosis: retroperitoneal liposarcoma. Management: refer to sarcoma surgery; image-guided core biopsy along planned tract; en bloc resection.

"An 80-year-old man with violaceous patches on the scalp present for 4 months, expanding."

— Diagnosis: cutaneous angiosarcoma. Next step: punch biopsy; not topical steroids, not observation.

"A 70-year-old woman 10 years post-mastectomy + axillary dissection + RT now with chronic lymphedema develops purple nodules on the arm."

— Diagnosis: Stewart-Treves angiosarcoma. Management: urgent biopsy, refer to sarcoma center; often requires aggressive surgery and systemic therapy.

"A 3-year-old girl with grape-like vaginal mass and bleeding."

— Diagnosis: botryoid embryonal rhabdomyosarcoma. Management: pediatric oncology referral, VAC chemotherapy + organ-sparing surgery/RT.

"A 55-year-old with 8 cm gastric mass, KIT-positive on biopsy, mitotic rate 8/50 HPF."

— Management: resection + adjuvant imatinib × 3 years (high-risk GIST).

"A 30-year-old, 10 years post-osteosarcoma treatment, presents with dyspnea on exertion."

— Next step: echocardiogram for anthracycline cardiomyopathy AND CT chest for pulmonary metastasis — but cardiac assessment is the typical first-order answer.

Stem 1 — The unplanned excision:

Stem 2 — The teenager with knee pain:

Stem 3 — The retroperitoneal mass:

Stem 4 — The "non-resolving bruise":

Stem 5 — The post-mastectomy arm:

Stem 6 — The young child with vaginal mass:

Stem 7 — Pre-imatinib GIST:

Stem 8 — Anthracycline survivor with dyspnea:

Board pearl: When in doubt on any stem with "soft tissue mass" or "bone lesion" — the answer is almost always image first (MRI), then refer to sarcoma center, then biopsy at that center. The wrong answers are "excise locally," "FNA," "observe."

One-Line Recap

Sarcomas are rare mesenchymal malignancies in which the single most important Step 3 principle is that any soft tissue mass >5 cm, deep to fascia, growing, or painful — or any aggressive-appearing bone lesion — warrants MRI and referral to a multidisciplinary sarcoma center BEFORE biopsy or excision, because the unplanned "whoops" procedure is the dominant preventable harm and recovery requires multimodal therapy at a high-volume center.

Recognition: the "5 cm rule" — size >5 cm, deep, growing, or painful triggers MRI + referral; teenagers with persistent night-time bone pain near the knee = osteosarcoma until proven otherwise; violaceous scalp patches in elderly = angiosarcoma; vaginal grape-like mass in a young child = botryoid rhabdomyosarcoma.

Diagnosis sequence: MRI of primary site → CT chest for staging → image-guided core biopsy at the sarcoma center via a tract the surgeon will excise; never excisional biopsy of an unknown deep or >5 cm mass; grade, size, and depth drive prognosis; key translocations (Ewing EWSR1-FLI1, synovial SS18-SSX, myxoid lipo FUS-DDIT3, GIST KIT) define subtype-specific therapy.

Treatment: wide R0 excision is the cornerstone; add radiation for high-grade, large, or deep STS; neoadjuvant/adjuvant chemo for osteosarcoma (MAP), Ewing (VDC/IE), and rhabdomyosarcoma (VAC); imatinib for GIST and DFSP; doxorubicin ± ifosfamide for most metastatic STS; surveillance is lung-focused with CT chest because pulmonary metastasectomy can be curative.

Safety and systems: centralize care at multidisciplinary sarcoma centers, disclose unplanned excisions transparently, refer for genetic counseling when Li-Fraumeni/NF1/RB1 features are present, monitor for anthracycline cardiomyopathy and therapy-related MDS lifelong, and remember that early referral — not heroic salvage surgery — is what saves limbs and lives.